News

Stories

See all

2021 Updates: Lilly's Global COVID-19 Response

View Story

Supporting United Way to Meet New Challenges

View Story

Racial Justice Initiative: Confronting Racial Inequities Head On

View Story

How Digital and Remote Health Can Help Next-Generation VBAs

View Story

Meet the Women Behind Our Cancer Research

View Story

Christalyn Rhodes, Ph.D.

Christalyn Rhodes: Living Her Purpose, Our Purpose

View Story


Press Releases

See all

Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes

March 4, 2021

Tags |  Product

Trial participants taking the highest dose of tirzepatide (15 mg) achieved an A1C reduction of 2.46 percent and weight loss of 12.4 kg (27.3 lb., 13.1 percent), double the weight reduction compared to those taking semaglutide 1 mg At the lowest dose of tirzepatide (5 mg), participants achieved A1C




Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

March 3, 2021

Tags |  Product

- Baricitinib met primary endpoint of hair regrowth across both dosing regimens - There are currently no FDA-approved treatments for AA INDIANAPOLIS , March 3, 2021 /PRNewswire/ --  Eli Lilly and Company  (NYSE: LLY) and  Incyte  (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a




Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19

February 26, 2021

Tags |  Product

INDIANAPOLIS , Feb. 26, 2021 /PRNewswire/ -- The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced. Bamlanivimab and etesevimab together recently received




Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions

February 25, 2021

Tags |  Product

COLUMBIA, Md. and INDIANAPOLIS , Feb. 25, 2021 /PRNewswire/ -- Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly 's connected insulin solutions, currently in development.